From the Research
Baclofen is not a recommended first-line treatment for migraines due to limited evidence supporting its effectiveness. The most recent and highest quality study available is from 2021 1, which discusses second-line interventions for migraine in the emergency department but does not mention baclofen as an effective option. Other studies, such as those from 2010 2, 2006 3, and earlier, provide information on various medications for migraine prophylaxis but do not strongly support the use of baclofen for this purpose. A study from 1999 4 found baclofen to be effective in reducing migraine frequency and severity, but this is an older study with limited sample size and not as robust as more recent research. Another study from 2003 5 mentions baclofen as a potential preventative treatment for migraine but notes the need for further clinical trials to determine its efficacy. Given the lack of strong, recent evidence supporting baclofen's use for migraines, it is recommended to consider first-line migraine preventive medications like topiramate, propranolol, amitriptyline, or newer CGRP antagonists, which have much stronger evidence supporting their use. Patients considering baclofen for migraines should discuss this option thoroughly with their healthcare provider, weighing the potential benefits against the side effects and the availability of other treatments with better-established efficacy. Key points to consider include:
- The typical dosage of baclofen when used for migraines
- Potential side effects like drowsiness, dizziness, and weakness
- The importance of gradual dose increase to minimize side effects
- The potential for withdrawal symptoms with abrupt discontinuation
- The need for careful consideration and discussion with a healthcare provider before starting baclofen for migraine management.